Literature DB >> 24191703

1.5T versus 3T MRI for targeting subthalamic nucleus for deep brain stimulation.

Cheng-Hsin Cheng1, Hsing-Ming Huang, Hung-Lin Lin, Shang-Ming Chiou.   

Abstract

BACKGROUND: Accurate stereotactic placement of the electrode into the subthalamic nucleus (STN) is imperative to the therapeutic efficacy of deep brain stimulation (DBS). However, it is not always possible to directly visualize the very small STN using 1.5T MR imaging.
OBJECTIVE: To evaluate whether 3T MR imaging can provide better identification of the STN and clinical outcome than 1.5T MR imaging.
METHODS: Thirty-nine patients with advanced Parkinson's disease underwent 1.5T (n = 16) or 3T (n = 23) fast spin echo T2-weighted (FSE-T2WI) MR imaging for targeting the STN. A semi-quantitative 3-point scoring system was proposed to rank the clearness of STN contour: Score "0" if non-visible; Score "1" if visible but with blurred margin; and "2" if visible with clear margin. The unified Parkinson's disease rating scale (UPDRS) was also compared before operation and post-operation.
RESULTS: The STN score was 2 in all the patients of the 3T group, whereas it was relatively blurred (mean score, 1.19) in the 1.5T group (P < 0.001). The number of microelectrode trajectories (1.2 versus 1.5; P < 0.05) was lower in the 3T group; consequently, the operative time was also less (P < 0.05) as compared with that in the 1.5T group. The outcome of UPDRS motor examination showed no significant difference in two groups.
CONCLUSION: 3T MR imaging is a reliable and more accurate method for direct targeting of the STN for DBS surgery. However, the technique of high-sequence MR imaging may not influence the clinical outcome significantly.

Entities:  

Keywords:  Parkinson's disease; deep brain stimulation; functional neurosurgery; magnetic resonance image; subthalamic nucleus

Mesh:

Year:  2013        PMID: 24191703     DOI: 10.3109/02688697.2013.854312

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  7 in total

Review 1.  Neuroimaging Technological Advancements for Targeting in Functional Neurosurgery.

Authors:  Alexandre Boutet; Robert Gramer; Christopher J Steele; Gavin J B Elias; Jürgen Germann; Ricardo Maciel; Walter Kucharczyk; Ludvic Zrinzo; Andres M Lozano; Alfonso Fasano
Journal:  Curr Neurol Neurosci Rep       Date:  2019-05-30       Impact factor: 5.081

2.  Patient's body composition can significantly affect RF power deposition in the tissue around DBS implants: ramifications for lead management strategies and MRI field-shaping techniques.

Authors:  Bhumi Bhusal; Boris Keil; Joshua Rosenow; Ehsan Kazemivalipour; Laleh Golestanirad
Journal:  Phys Med Biol       Date:  2021-01-14       Impact factor: 3.609

3.  Microleakage beneath orthodontic brackets in high field magnetic resonance imaging (MRI) AT 1.5 & 3 Tesla.

Authors:  Esra Bolat Gümüş; Samed Şatir; Alper Kuştarci
Journal:  Dentomaxillofac Radiol       Date:  2022-02-09       Impact factor: 3.525

4.  Deep Learning-Based Deep Brain Stimulation Targeting and Clinical Applications.

Authors:  Seong-Cheol Park; Joon Hyuk Cha; Seonhwa Lee; Wooyoung Jang; Chong Sik Lee; Jung Kyo Lee
Journal:  Front Neurosci       Date:  2019-10-24       Impact factor: 4.677

5.  Volumetric analysis of subthalamic nucleus and red nucleus in patients of advanced Parkinson's disease using SWI sequences.

Authors:  Swapnil Kolpakwar; Abhishek J Arora; S Pavan; Rukmini M Kandadai; Rajesh Alugolu; M Vijaya Saradhi; Rupam Borgohain
Journal:  Surg Neurol Int       Date:  2021-07-27

6.  The clinical utility of fMRI for identifying covert awareness in the vegetative state: a comparison of sensitivity between 3T and 1.5T.

Authors:  Davinia Fernández-Espejo; Loretta Norton; Adrian M Owen
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

7.  General Anesthesia versus Local Anesthesia in StereotaXY (GALAXY) for Parkinson's disease: study protocol for a randomized controlled trial.

Authors:  R A Holewijn; D Verbaan; R M A de Bie; P R Schuurman
Journal:  Trials       Date:  2017-09-07       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.